Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam

Completed

• Conditions: Epilepsy

• Registration Number: NCT00319605
• Lead Sponsor: UCB Pharma

Brief Summary

Phase IV, observational, post-authorization, cross sectional, open-label, multicenter study to evaluate the acceptability of oral solution of levetiracetam in patients with partial epilepsy as assessed by a questionnaire.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-04
• Study First Posted: 2006-04-27
• Study First Submitted: 2006-04-28
• Study First Submitted QC: 2006-04-28
• Primary Completion: 2006-07
• Study Completion: 2006-07
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-24
• Last Update Posted: 2012-05-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Patients 16 years old or older diagnosed with partial epilepsy with or without generalization receiving levetiracetam oral solution for at least 28 days before the study

Exclusion Criteria

• Patients with disturbances of the sense of taste and smell that can interfere with the assessment of the parameters of the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified